Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes

被引:129
作者
Ogata, Kiyoyuki
Kishikawa, Yoshifumi
Satoh, Chikako
Tamura, Hideto
Dan, Kazuo
Hayashi, Akio
机构
[1] Nippon Med Coll, Inst Gerontol, Div Hematol, Tokyo 1138603, Japan
[2] Nippon Med Coll, Inst Gerontol, Dept Bioregulat, Tokyo 1138603, Japan
[3] Nippon Med Coll, Dept Med, Tokyo 1138603, Japan
[4] Mitsubishi Kagaku Bioclin Labs, Dept Res & Dev, Tokyo, Japan
关键词
D O I
10.1182/blood-2005-12-4916
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The diagnosis of myelodysplastic syndromes (MDS) without an increase in blasts and ringed sideroblasts (low-grade MDS without ringed sideroblasts [LGw/ oRS]) may be problematic because dysplastic features are not specific to MDS and approximately 50% of patients with LGw/oRS lack chromosomal aberrations. Here, we report the usefulness of flow cytometric characteristics of CD34(+) cells for LGw/oRS diagnosis. Bone marrow cells from LGw/oRS patients and controls (eg, cytopenic individuals without MDS) were analyzed using 4-color flow cytometry (FCM). We objectively determined reference ranges of 13 parameters related to CD34(+) cells with data from controls. In LGw/oRS; patients, various abnormalities of CD34(+) cells-eg, decrease in CD34(+) B-cell precursors, aberrant expression or overexpression of various antigens on CD34(+) myeloblasts-were observed. We constructed a reproducible, flow cytometric scoring system for LGw/oRS diagnosis. High scores were observed in 16 of 27 LGw/oRS patients, regardless of the presence or absence of chromosomal aberrations, but not in any of the 90 controls. Among LGw/oRS patients with chromosomal aberrations, patients with trisomy 8 or del20(q) had low FCM scores (P =.002). As a result, most LGw/oRS patients were identified based on high FCM score, chromosomal aberration, or both.
引用
收藏
页码:1037 / 1044
页数:8
相关论文
共 38 条
[1]  
[Anonymous], 2000, IMMUNOPHENOTYPING
[2]   The relationship between the myelodysplastic syndromes and the myeloproliferative disorders [J].
Bain, BJ .
LEUKEMIA & LYMPHOMA, 1999, 34 (5-6) :443-+
[3]   A comparative review of classification systems in myelodysplastic syndromes (MDS) [J].
Bennett, JM .
SEMINARS IN ONCOLOGY, 2005, 32 (04) :S3-S10
[4]  
BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x
[5]   Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes [J].
Bowen, D ;
Culligan, D ;
Jowitt, S ;
Kelsey, S ;
Mufti, G ;
Oscier, D ;
Parker, J .
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 120 (02) :187-200
[6]   A retrospective analysis of myelodysplastic syndromes with thrombocytosis:: reclassification of the cases by WHO proposals [J].
Cabello, AI ;
Collado, R ;
Ruiz, MA ;
Martínez, J ;
Navarro, I ;
Ferrer, R ;
Sosa, AM ;
Carbonell, F .
LEUKEMIA RESEARCH, 2005, 29 (04) :365-370
[7]   Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome [J].
Elghetany, MT .
BLOOD, 2002, 99 (01) :391-391
[8]   International scoring system for evaluating prognosis in myelodysplastic syndromes [J].
Greenberg, P ;
Cox, C ;
LeBeau, MM ;
Fenaux, P ;
Morel, P ;
Sanz, G ;
Sanz, M ;
Vallespi, T ;
Hamblin, T ;
Oscier, D ;
Ohyashiki, K ;
Toyama, K ;
Aul, C ;
Mufti, G ;
Bennett, J .
BLOOD, 1997, 89 (06) :2079-2088
[9]  
HAMBLIN T, 1992, LEUKEMIA RES, V16, P3, DOI 10.1016/0145-2126(92)90090-T
[10]  
KIBBELAAR RE, 1992, BLOOD, V79, P1823